Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03075072 · ClinicalTrials.gov registry record · NA
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
A NA study of Brain Metastases, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 196
- Enrollment target
- 2
- Study locations
NCT03075072: Active NA study of Brain Metastases, sponsored by Dana-Farber Cancer Institute.
NCT03075072 is a NA study of Brain Metastases that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 196 participants, roughly in line with the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03075072, a NA study of Brain Metastases, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 196 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)
Primary Outcome
Questionnaire - MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT)
Conditions Studied
Interventions
- RADIATION Whole brain radiation
- RADIATION Stereotactic radiation (SRS)
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2017-04-10 |
| Est. Completion | 2025-09-30 |
| Phase | NA |
What the registry record for NCT03075072 still lists
NCT03075072 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 2 interventions - of which Whole brain radiation is the first listed.
NCT03075072 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03075072 about?
NCT03075072 is a clinical study titled "Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial". This research study is studying two different types of radiation as treatment for brain metastases (tumors in the brain that spread from a cancer that originated elsewhere in the body)
What is the current status of trial NCT03075072?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 196 participants. The study started on 2017-04-10. Estimated completion is 2025-09-30.
What conditions does trial NCT03075072 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT03075072?
The interventions under investigation include: Whole brain radiation (RADIATION), Stereotactic radiation (SRS) (RADIATION).
Who is sponsoring clinical trial NCT03075072?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03075072 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03075072's enrollment target sits among peer trials
196 6th of 67 higher than 62 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
RECRUITING · NA
-
REMASTer: REcurrent Brain Metastases After SRS Trial
RECRUITING · NA
-
Development of MRF for Characterization of Brain Tumors After Radiotherapy
RECRUITING · NA
-
MeDex: No Perioperative Dexamethasone in Brain Metastases
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI